Tenderwize
Zurück zur Suche

Open-house rebate agreement for Omalizumab

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 35 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Omalizumab (ATC-Code nach WHO: R03DX05)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

The notice says participation documents must be obtained from the DTVP project space after access approval, and further...

Only pharmaceutical undertakings under § 4(18) AMG for the offered product may participate; local representatives quali...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive pharmaceutical rebate agreement for medicines containing Omalizumab.
  • Open-house participation model with no individual negotiations.
Vollständige Zusammenfassung anzeigen

Open-house supply arrangement for the active substance Omalizumab (ATC R03DX05) with AOK PLUS. It is a non-exclusive pharmaceutical rebate agreement under § 130a(8) SGB V, open to all interested pharmaceutical companies that meet the stated participation conditions. No individual negotiations or delivery exclusivity apply. The notice states that quantities are unknown and minimum purchase volumes are not guaranteed. Participation documents are available via DTVP project space, but the extracted procurement documents were not provided for analysis.

Risiken

The notice says participation documents must be obtained from the DTVP project space after access approval, and further...

Only pharmaceutical undertakings under § 4(18) AMG for the offered product may participate; local representatives quali...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.

Eligibility

  • Required documents explicitly mentioned: completed declaration of no exclusion grounds and declaration regarding Russia sanctions.

Administrative

  • Participation documents must be obtained via the DTVP project space after access approval.

Auftraggeber

Ort

Erfurt, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE256878834

Tätigkeit

Health

Lose (1)

LOT-0001

Open-house rebate agreement for Omalizumab

Non-exclusive supply arrangement for pharmaceutical products containing Omalizumab (ATC R03DX05). The lot is an open-house model, so any eligible pharmaceutical company may join during the participation period. No exclusivity, no guaranteed minimum quantities, and no individual contract negotiations are stated. Performance location is Dresden, Germany, with coverage indicated for Saxony and Thuringia in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Ort

Dresden, Germany

Dauer

Sep 2025 - Sep 2026

Kategorie

Pharmaceutical products

Frist

Deadline Sep 30, 2026

Vergabedetails

Veröffentlichungsdatum
24 Aug 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
552774-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3